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ABSTRACT 
Model of study: A cross-sectional study was conducted. Objective: to evaluate the association between 
self-efficacy and socio-demographic and clinical variables in patients with type 2 diabetes mellitus (T2DM). 
Method: The sample was composed by 111 patients with T2DM in use of insulin, in primary health care 
units and outpatient setting in the southeast region of São Paulo state, Brazil. Sociodemographic data 
were gathered using validated questionnaire and clinical data were obtained from medical and health 
records. Self-efficacy was assessed by the Brazilian version of Insulin Management Diabetes Self-Efficacy 
Scale (IMDSES). The data were submitted to descrip-tive and comparative analyses using Mann-Whitney 
and Kruskal-Wallis to verify association be-tween socio- demographic/clinical variables and self-efficacy. 
Results: Self-efficacy was associ-ated with schooling level and presence of comorbidities, such as 
coronary artery disease, dyslipidemia, obesity, peripheral arterial disease and peripheral neuropathy. 
Conclusion: The findings provide support to the design some specifics interventions aimed at improving 
the self-efficacy of patients with T2DM on insulin use. 
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RESUMO 
Modelo do estudo: Foi conduzido um estudo transversal. Objetivo: verificar a associação entre 
autoeficácia e variáveis sociodemográficas e clínicas em pacientes com diabetes mellitus. Métodos: A 
amostra foi composta por 111 pacientes com diabetes mellitus tipo 2 em uso de insulina em unidade 
básica de saúde e em ambulatório de hospital universitário da região sudeste do Estado de São Paulo, 
Brasil. Os dados sociodemográficos foram coletados usando questionário 
 
 
1. Registered Nurse (RN), Ph.D student.   
  Universidade de Campinas, Faculdade de  
  Enfermagem. Campinas, SP, Brasil. 
2. RN, Ph.D. Universidade de Campinas, Faculdade  
      de Enfermagem. Campinas, SP, Brasil. 
3. RN, PhD, Professor. Universidade Federal de São 
   João Del-Rei, Campus de Divinópolis, MG, Brasil. 
4. RN, PhD, Professor; Universidade de Campinas, 
  Faculdade de Enfermagem. Campinas, SP, Brasil. 
 
Disclosure of potential conflicts of interest: The 
authors have no conflicts of interest to disclose. 
 
Corresponding 
Danilo Donizetti Trevisan 
Universidade Federal de São João Del-Rei, 
Av. Sebastião Gonçalves Coelho, 400. Chanadour. 
35501-296 - Divinópolis - MG, Brazil 
 
Recebido em 03/10/2017 
Aprovado em 26/06/2018 
 
Medicina (Ribeirão Preto, Online.) 2018;51(2):112-20 http://dx.doi.org/10.11606/issn.2176-7262.v51i2p112-120 
Artigo original 
Self-efficacy in patients with Diabetes mellitus 
 
 
 
validado e os dados clínicos foram obtidos dos prontuários do hospital e da unidade básica de saúde. A 
medida da autoeficácia foi obtida por meio da aplicação da Insulin Management Diabetes Self-Efficacy 
Scale – IMDSES. Para verificar a associação entre as variáveis sociodemográficas / clínicas e a autoeficácia 
foram utilizados os testes de Mann-Whitney e Kruskal-Wallis. Resulta-dos: A autoeficácia foi associada 
à escolaridade, presença de comorbidades e complicações do DM, como doença arterial coronária, 
obesidade, doença arterial periférica e neuropatia periférica. Conclusão: Os achados subsidiam o 
delineamento de intervenções para otimizar a autoeficácia em pacientes com diabetes mellitus em uso 
de insulina. 
 
Palavras-chave: Diabetes Mellitus. Autoeficácia. Estudos Transversais. Enfermagem. 
 
 
 
INTRODUCTION 
 
Approximately 347 million people are af- 
fected by diabetes mellitus (DM) worldwide.1 In 
Brazil, in 2013, it was estimated that just under 
12 million in the age group of 20-79 years old were 
affected by DM and costs for their treatment and 
monitoring may reach 3.9 billion dollars  a year to 
the government.2,3 
The development of strategies to provide 
behavior change and adoption of healthy prac- tices 
(i.e., healthy food behavior, physical activity, self-
monitoring of blood glucose, meticulous foot care 
and adherence to medication) is essential to 
manage and control the disease.4 
Sociodemographic characteristics have been 
observed to affect the severity of DM. Edu-cational 
level, for example, is a key determinant of DM 
mortality in both sexes, and is more rel-evant in 
women, while marital status also plays an 
outstanding role in men.5 Increased risk of 
cardiovascular diseases, cancer and mortality are 
well stablished among patients with Type-2 Dia- 
betes Mellitus (T2DM).6 
The literature has reported that psychoso- 
cial factors such as self-efficacy also affect – posi- 
tively or negatively – the medication adherence of 
the patients with T2DM. Therefore, factors as 
perceptions related to their illness including symp- 
toms, consequences and curability; perceptions of 
medications including safety concerns, conven- 
ience and their necessity; religious healing prac- 
tices and beliefs; perceptions about and experi- 
ences with their healthcare providers and the 
healthcare system including the availability of 
medications and diabetes education – were per- 
ceived as barriers to adhere to drug treatment. 
 
Nevertheless, perceived self-efficacy and social 
support were assessed as facilitators in engag-ing 
in T2DM drug treatment.7 
The self-efficacy construct refers to one’s 
beliefs or confidence in their ability to successfully 
perform a task to achieve the desired outcome.8 
This construct assumes that the initiation, main- 
tenance or withdrawal of a behavior is also influ- 
enced by the person’s beliefs in his/hers ability to 
overcome environmental barriers to implementa- 
tion.9 Therefore, there are reports suggesting that 
strengthening self-efficacy relates to healthy 
behaviors in patients with type (T2DM).10,11 Previ- 
ous studies10,12 have shown that self-efficacy in- 
fluenced self-care behavior in Chinese and Ameri- 
cans patients with T2DM. 
However, the association between self-ef- 
ficacy and sociodemographic and clinical variables 
in patients with T2DM in the Brazilian context has 
been little investigated. The elucidation of this 
association should provide support for the devel- 
opment of specific interventions aimed at improv- 
ing self-efficacy of patients with T2DM. 
Considering the importance of self-efficacy in 
the management of T2DM, this study was aimed at 
evaluating the association between self-effi- cacy 
and sociodemographic and clinical variables in 
T2DM outpatients. 
 
METHODS 
 
Design and Setting 
A cross-sectional study was carried out in a 
primary health unit and in an outpatient setting at 
a university hospital, in the southeast region of São 
Paulo state, Brazil. 
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Participants and data collection 
 
This study enrolled 111 patients with T2DM in 
regular follow up at the above-mentioned set- tings, 
aged over 18 years old. We included T2DM 
oupatients on insulin use for at least one year and 
with oral communication skills – those capa-ble of 
comprehending and speaking Brazilian Por- 
tuguese in order to be interviewed. Those pa- tients 
with chronic complications of T2DM in the advanced 
stage, as chronic renal failure under- going 
hemodialysis, blindness, heart failure class III and 
IV and those patients with physical se- quelae of 
stroke, were excluded. 
The data were collected by two of the re- 
searchers (RAN and DDT) by interview, in a pri- 
vate room, during the interval between medical 
and/or nursing appointments in referenced fields of 
research. 
The patient was initially approached to ex- 
posure the aim of the study and obtaining the 
agreement to engage in study by signing the In- 
formed Consent Form. Then, the structured inter- 
view technique was used to gather sociodemo- 
graphic and clinical data, as well as measure self- 
efficacy by application of the Brazilian version of 
IMDSES scale.13 After, the complementary clinical 
data (length of T2DM diagnosis, comorbidities, 
fasting glucose and glycated hemoglobin – HbA1c) 
was obtained. 
 
Data collection 
 
Sociodemographic and clinical variables 
The sociodemographic and clinical data were 
obtained by previously validated instru- ment,14 
consisting of the items: 
• Sociodemographic data: gender, age, school- 
ing (completed years of education), family ar- 
rangement, employment and personal and fam- 
ily monthly income in minimum wages; 
• Clinical data: lenght of diagnosis and treatment 
of T2DM, length of insulin use, number of classes 
of medications in use, habits (smoking) and 
comorbidities - hypertension, coronary artery 
disease (myocardial infarction or angina), stroke, 
dyslipidemia, obesity (evaluated by the 
 
 
body mass index – BMI ³ 30.0 kg/m2), meta- 
bolic syndrome and peripheral arterial disease. 
Data on symptoms perceived over the prior 
month to the interview (such as involuntary 
weight loss, fatigue or blurred vision); signals as 
hyper/hypoglycemia and complications of T2DM 
(retinopathy and neuropathy) were en-rolled. 
Anthropometric data were obtained (weight, 
abdominal circumference height, waist 
circumference) and laboratorial exams results 
(fasting glucose and HbA1C) – were gathered if 
they were collected up to three months before the 
interview. 
Insulin Management Diabetes Self- 
Efficacy Scale – IMDSES 
The IMDSES was created in American cul- 
ture by Hurley and Harvey15 to measure self-effi- 
cacy related to self-care of DM between patients on 
insulin therapy.15,16 The scale is composed of 28 
items, which measure seven types of behavior: 
general, diet, exercise, foot care, blood glucose 
monitoring, insulin administration; and detection, 
prevention   treatment  of hypoglycemia/hyper- 
glycemia. The items are distributed  over  three 
subscales: General, Diet and Insulin. 
As for the scoring, the answers are rated on 
a Likert-type scale of six points (1=strongly agree, 
2=moderately agree, 3= slightly agree, 4= slightly 
disagree, 5 = moderately disagree, 6 = strongly 
disagree). In the original scale, the items (4, 8, 9, 
13, 16, 22, 25 and 26) were set in nega-tive mode. 
The psyhometric properties of the origi-nal version 
presented satisfactory evidences of reliability by 
Cronbach’s alpha coefficient (α) – total score (α= 
0.82), General (α=0.67), Diet (α=0.78) and Insulin 
(α=0.77). 
The Brazilian version of IMDSES, proposed by 
Gastal et al.,13 is composed by 20 items, dis- 
tributed in the same domains, since the items which 
presented factor loadings < 0.30 in factor analysis 
were excluded (12, 13, 14, 15, 16, 17, 18, and 25). 
In this version, the sequence of items was modified 
and some of them (4, 8, 9, 22, 25 and 26) were set 
in affimative mode. One item (item 20) had its text 
slightly modified. The an- swers are rated on a 
Likert-type scale of four points (1=strongly agree, 
2= agree, 3= disagree and 4 = strongly disagree) 
and the option “d
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not apply” was included. The scoring was obtained 
by the sum of the scores, which ranged from 28 
to112; in the item 13 (drafted in the negative 
mode) reverse scoring was used for calculating the 
total score. For the interpreting the Brazilian 
version of IMDSES, the higher the score, the lower 
the self-efficacy. 
Nevertheless, in our study, the 28-item Bra- 
zilian version was chosen, in order to allow com- 
parison between current results and those of the 
original scale. Therefore, items are distributed over 
subscales as following: from 1 to 11, in the Diet 
subscale; from 12 to 18, in the Insulin subscale; 
and from 19 to 28, in the General subscale. The 
total score comprises the sum of the three sub-
scales. The complete Brazilian version of IMDSES 
showed evidence of reliability by Cronbach’s al-pha 
coefficient for Insulin (α=0.82) and Diet (α=0.64) 
subscales. The  General subscale pre-sented α of 
0.50. 
 
Data analyses 
 
The Statistical Package for the Social Sci- 
ences (SPSS) for Windows, version 21.0 was used 
for the analysis. Frequency tables, position meas- 
urements (mean, median and range) and disper- 
sion (standard deviation) were used for the de- 
scriptive analysis of sociodemographic/clinical vari-
ables and scores of the Brazilian version of IMDSES. 
Reliability regarding internal consistency was 
estimated by Cronbach’s alpha (α) coefficient and it 
was established α >.70 as evidence of in- ternal 
consistency. Mann-Whitney and Kruskal- Wallis test 
were used to compare self-efficacy across 
sociodemographic (gender, age, education, place of 
residence, family structure and family in- come) 
and clinical variables (co-morbidities symp- toms, 
DM complications, blood glucose and HbA1c). A 
significance level of 5% was adopted. 
 
Ethical considerations 
 
The local ethics committee approved the 
study (Protocol: nº 1180/2011). The authors (RAN 
and DDT) explained the aim of the study and pro- 
cedure of data collection to potential participants. 
The enrolled patients signed the Informed Con- 
sent. 
RESULTS 
 
We found a predominance of women 
(64.8%), whose mean age was of 58.2 (9.0) years 
old, with an average schooling of 6.1 (4.5) years of 
study, who lived with partners and/or other family 
members (90.9%). Regarding clinical pro- file, the 
average length of treatment of T2DM  was 
14.5 (9.2) years, with a mean insulin use length of 
7.5 (6.7) years. Concerning the comorbidities, 
hypertension (54.1%) and obesity (64.9%) stood 
out. The blurred vision was the most often re- 
ported symptom (45.9%), on the month prior to the 
interview. The findings showed average HbA1C 
level above recommended (see Table 1). 
The results showed higher IMDSES scores for 
the General subscale and for the total score, which 
indicate lower self-efficacy relating to self- care of 
diabetes (Table 2). 
The patients with lower schooling levels, 
which reported less than or equal to three com- 
pleted years of study, had lower self-efficacy in the 
General subscale, compared to those who reported 
greater than or equal to three completed years of 
study (p=0.05; Mann-Whitney test) (Ta- ble 3). 
The data showed smaller self-efficacy scores 
of IMDSES for the Diet subscale among patients 
with coronary artery disease (p-value=0.04) and 
greater self-efficacy for those who presented weight 
reduction (p-value=0.02). Regarding the Insulin 
subscale, greater self-efficacy was observed among 
those who had dyslipidemia (p- value=0.006). As 
for the General subscale,  smaller self-efficacy was 
observed among those who had: CAD (p-
value=0.02), dyslipidemia (p- value=0.01), obesity 
(p-value=0.04), peripheral artery disease (p-
value=0.03) and peripheral neu- ropathy (p-
value=0.002) (see Table 4). 
 
DISCUSSION 
This study was aimed at evaluating the as- 
sociation between self-efficacy and sociodemo- 
graphic and clinical variables in T2DM outpatients. 
The main findings showed that self-efficacy meas- 
ured by the Brazilian version of the IMDSES was 
associated with socio-demographic variables 
(schooling) and clinical variables, especially with 
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Table 1. 
Sociodemographic and clinical profile of outpatients with type 2 diabetes mellitus, in use of insulin (n=111). 
 
 
Socio-demographic and clinical variables 
 
% (n) Mean (SD)
*
 
 
Median 
 
Range 
Gender 
    
Female 64.8 (72) 
   
Age (in years) 
 
58.2 (9.0) 58.0 34.0-81.0 
Schooling 
Living with: 
Alone 
 
 
 
9.0 (10) 
6.1 (4.5) 5.0 0.0-25.0 
Partner and/or family member 90.9 (101)    
 
Smoking 
 
Yes 11.7 (13) 
No 88.3 (98) 
 
DM Treatment time  
Onset of treatment 14.5(9.2) 14.0 1.0-40.0 
Onset of using insulin 7.5(6.7) 5.0 0.0-32.0 
 
Symptoms (month before the interview) 
   
 
Nephropathy 27.0 (30) 
Retinopathy 42.3 (47) 
Peripheral neuropathy 21.6 (24) 
Comorbidities 
  
Hypertension 54.1 (60) 
Coronary artery disease 17.1 (19) 
Stroke (without cognitive deficit) 9.0 (10) 
Dyslipidemia 41.4 (46) 
Obesity 64.9 (72) 
Metabolic syndrome 41.4 (46) 
Peripheral Arterial Disease 9.9 (11) 
 
Complications of DM 
  
Nephropathy 27.0 (30) 
Retinopathy 42.3 (47) 
Peripheral neuropathy 21.6 (24) 
 
Tests results 
  
 
Fasting glucose 172.3(104.1) 140.0 53.0-800.0 
HbA1C 9.4 (2.1) 9.2 5.9-14.9 
Note: *SD = Standard Deviation. 
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Table 2. 
Descriptive analysis of the performance of the Brazilian version of Insulin Management Diabetes Self-Efficacy Scale – 
IMDSES in outpatients with type 2 diabetes mellitus (T2DM) in use of insulin (n=111). 
 
 
IMDSES subscales 
Number of items Mean (SD)
* 
Median Range 
 
Diet 11 2.4 (0.3) 2.4 1.5-3.4 
Insulin 07 1.8 (0.5) 1.8 0.6-3.0 
General 10 2.6 (0.4) 2.6 1.7-3.6 
Total Score 28 6.8 (0.7) 6.8 4.6-8.9 
Note: *SD = Standard Deviation. 
 
 
 
 
Table 3. 
Comparison analysis between of Brazilian version of Insulin Management Diabetes Self-Efficacy Scale – IMDSES 
and socio-demographic variables in outpatients with type 2 diabetes mellitus (T2DM) (n = 111). 
 
 
Self-efficacy – IMDSES 
 
 
Sociodemographic variables 
Diet 
Mean(SD) 
Insulin 
Mean(SD) 
General 
Mean(SD) 
Total score 
Mean (SD) 
Gender 
Female 
 
2.4(0.3) 
 
1.7(0.5) 
 
2.6(0.4) 
 
6.8(0.7) 
Male 2.4(0.4) 1.8(0.5) 2.6(0.4) 6.8(0.7) 
p-value* 0.67 0.15 0.80 0.59 
Age 
    
18  years old  60 2.4(0.3) 1.7(0.4) 2.6(0.4) 6.7(0.6) 
> 60 years old 2.4(0.4) 1.9(0.5) 2.6(0.4) 7.0(0.8) 
p-value* 0.39 0.08 0.41 0.15 
Education 
    
 3 years of study 2.4(0.3) 1.9(0.6) 2.7(0.4) 7.0(0.8) 
> 3 years of study 2.4(0.4) 1.7(0.4) 2.6(0.4) 6.7(0.6) 
p-value* 0.77 0.05 0.23 0.08 
Living with 
    
Alone 2.5(0.3) 1.7(0.4) 2.8(0.4) 6.9(0.6) 
Partner/family member 2.4(0.3) 1.8(0.5) 2.6(0.4) 6.8(0.7) 
p-value* 0.37 0.49 0.24 0.54 
Family income 
    
 1 MW 2.4(0.4) 1.7(0.5) 2.8(0.4) 6.9(0.8) 
2  MW  4 2.4(0.3) 1.7(0.5) 2.6(0.4) 6.8(0.7) 
> 4 MW 2.4(0.3) 1.7(0.4) 2.7(0.4) 6.7(0.6) 
p-value† 0.95 0.10 0.22 0.94 
Note: 
a
Mann-Whitney test; †Krukal-Wallis test; MW= Minimum Wages. 
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Table 4. 
Comparison analysis between of Brazilian version of Insulin Management Diabetes Self-Efficacy Scale – 
IMDSES and clinical variables in outpatients with type 2 diabetes mellitus (T2DM) (n = 111). 
Self-efficacy – IMDSES 
 Diet Insulin General Total score 
Clinical variables Mean(SD) Mean(SD) Mean(SD) Mean (SD) 
Co-morbidities 
Hypertension 
 
Yes 2.4(0.2) 
 
1.8(0.3) 
 
2.5(0.4) 
 
6.6(0.5) 
 No 2.4(0.4) 1.8(0.5) 2.6(0.4) 6.8(0.7) 
 p-value* 1.0 0.91 0.06 0.31 
Coronary artery disease Yes 2.4(0.3) 1.8(0.4) 2.6(0.4) 6.7(0.6) 
 No 2.5(0.4) 1.7(0.6) 2.7(0.4) 7.0(0.8) 
 p-value* 0.04 0.64 0.02 0.07 
Dyslipidemia Yes 2.3(0.3) 2.0(0.3) 2.5(0.3) 6.7(0.5) 
 No 2.4(0.3) 1.7(0.5) 2.7(0.4) 6.8(0.8) 
 p-value* 0.08 0.006 0.01 0.67 
Stroke Yes 2.4(0.3) 1.8(0.5) 2.6(0.4) 6.8(0.7) 
 No 2.5(0.4) 1.9(0.4) 2.5(0.4) 6.9(0.8) 
 p-value* 0.27 0.55 0.31 0.41 
Obesity Yes 2.3(0.3) 1.9(0.4) 2.5(0.4) 6.7(0.6) 
 No 2.4(0.3) 1.7(0.5) 2.6(0.4) 6.8(0.7) 
 p-value* 0.08 0.09 0.04 0.22 
Metabolic syndrome Yes 2.3(0.3) 1.9(0.4) 2.6(0.3) 6.8(0.7) 
 No 2.4(0.4) 1.7(0.5) 2.6(0.4) 6.8(0.7) 
 p-value* 0.17 0.16 0.28 0.75 
Peripheral Arterial Disease Yes 2.4(0.3) 1.8(0.5) 2.6(0.4) 6.7(0.6) 
 No 2.4(0.4) 1.8(0.5) 2.8(0.4) 7.1(0.9) 
 p-value* 0.39 0.75 0.03 0.08 
Complications of DM 
Nephropatthy 
 
Yes 2.4(0.3) 
 
1.8(0.5) 
 
2.6(0.4) 
 
6.8(0.7) 
 No 2.4(0.4) 1.8(0.5) 2.6(0.4) 6.8(0.8) 
 p-value* 0.76 0.76 0.69 0.60 
Retinopathy Yes 2.3(0.4) 1.9(0.5) 2.7(0.4) 7.0(0.8) 
 No 2.4(0.3) 1.7(0.4) 2.6(0.4) 6.7(0.7) 
 p-value* 0.43 0.09 0.24 0.49 
Peripheral neuropathy Yes 2.4(0.3) 1.8(0.3) 2.5(0.3) 6.7(0.6) 
 No 2.4(0.4) 1.8(0.5) 2.7(0.4) 6.9(0.8) 
 p-value* 0.96 0.96 0.002 0.07 
Symptoms 
Hyperglycemia / hypoglycemia 
 
Yes 2.4(0.3) 
 
1.8(0.4) 
 
2.5(0.3) 
 
6.7(0.6) 
 No 2.4(0.4) 1.7(0.5) 2.7(0.4) 6.8(0.9) 
 p-value* 0.53 0.36 0.06 0.48 
Blurred vision Yes 2.4(0.4) 1.7(0.5) 2.6(0.4) 6.7(0.7) 
 No 2.4(0.3) 1.8(0.5) 2.6(0.4) 6.7(0.7) 
 p-value* 0.21 0.34 0.72 0.08 
Weight reduction Yes 2.5(0.3) 1.8(0.5) 2.7(0.4) 6.9(0.7) 
 No 2.3(0.3) 1.8(0.4) 2.5(0.4) 6.6(0.6) 
 p-value* 0.02 0.67 0.09 0.09 
Laboratorial results 
HbA1C 
 
< 6,0 2.4(0.4) 
 
1.7(0.5) 
 
2.6(0.4) 
 
6.7(0.7) 
 6,0 – 8,6 2.3(0.2) 2.1(0.8) 2.2(0.7) 6.6(0.8) 
 >8,6 2.4(0.3) 1.8(0.5) 2.6(0.4) 6.8(0.7) 
 p-value† 0.57 0.48 0.64 0.67 
Fasting glucose <70 2.5(0.4) 1.7(0.7) 2.4(0.7) 6.6(0.9) 
 70 – 100 2.4(0.3) 1.8(0.4) 2.4(0.3) 6.6(0.7) 
 >100 2.4(0.4) 1.8(0.5) 2.6(0.4) 6.8(0.7) 
 p-value† 0.95 0.97 0.08 0.62 
Note: *Mann-Whitney test; †Kruskal-Wallis test. 
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comorbidites (coronary artery disease, obesity, 
peripheral arterial disease) and peripheral neu- 
ropathy - one of the complications of T2DM. 
The relationship between self-efficacy and 
the incorporation of health behavior has been 
explored in several studies.17,18 As regarding the 
T2DM, which is a chronic disease, whose treat- 
ment imposes a significant change in patient’s life- 
style, the self-efficacy has been pointed as one of 
the variables present in strategies used to achieve 
the goal of changing behavior. 
In our study, when analyzing the associa- 
tion between self-efficacy and sociodemographic 
and clinical variables, there was a statistically sig- 
nificant association between schooling level and the 
General subscale of the Brazilian version of 
IMDSES. Similar finding has been evidenced in pre-
vious studies,17,19 which was demonstrated 
that schooling level was a significant predictor of 
self-efficacy. 
As regarding the comparison analysis be- 
tween self-efficacy and clinical variables, we found 
statistically significant association between pa- 
tients with a lower score of self-efficacy in the 
Insulin and General subscales of IMDSES and pres-
ence of comorbidities. A previous study,20 which 
enrolled 388 patients with T2DM, showed that 
people without comorbidities and T2DM complica-
tions were more confident to perform the activi-ties 
required for T2DM treatment. However, an-other 
study21 conducted with ethnically diverse 
individuals, showed no association between self- 
efficacy and comorbidities, such as hypertension 
and dyslipidemia. 
Our study also showed higher total scores, 
indicating greater impairment of total self-efficacy 
level among the subjects who had T2DM compli- 
cations. Therefore, the current data suggest that the 
severity of the T2DM, considering the presence of 
comorbidities, complications of T2DM and irregu-lar 
metabolic control, was associated with minor self- 
efficacy to manage the disease. This result shows the 
pivotal role of nurses in recognizing the vulnerability of 
these patients in the management of T2DM and the 
critical need of outlining interven-tions aimed to 
improve patients’s understanding about the treatment 
regimen and skills to use in-sulin, strengthening their 
self-efficacy in the man-agement and adherence to 
medication. 
 
The findings of this study subsidize a bet-ter 
comprehension of the association between self- 
efficacy and sociodemographic and clinical 
variables. Further studies are recommended in 
order to investigate self-efficacy barriers and/or 
facilitators to adherence to medication and non- 
medication treatment of patients with T2DM. 
 
CONCLUSION 
The findings of this study suggest that low 
schooling level and the presence of comorbidities 
and complications of T2DM were significantly as- 
sociated with lower self-efficacy in patients with 
T2DM on insulin therapy. These data subsidizes the 
design of specific interventions aiming at in- crease 
self-efficacy for the treatment and, hence, the 
better management of the disease in T2DM 
outpatients. 
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